Colorectal Cancer Clinical Trial
Official title:
The Acceptability and Feasibility of a Diet and Physical Activity Intervention to Prevent Recurrence in Colorectal Cancer Survivors: a Phase 2 Study
Background - Colorectal cancer (CRC) incidence is increasing at an alarming rate in Hong
Kong. A recent report concluded physical activity (PA) protects against colon cancer and
foods low in dietary fibre, red meat and processed meat cause CRC. Yet, the influence of
lifestyle factors on cancer outcome (i.e. recurrence and survival rates) in CRC survivors is
largely unknown.
Objectives & hypothesis - Our study aims to evaluate the acceptability of two behavioural
interventions for CRC survivors intended to improve cancer outcome and designed to (1)
increase PA levels and (2) reduce consumption of a Western diet.
The investigators hypothesize that the proposed interventions are (1) efficacious in
changing the two targeted behaviours; and (2) acceptable to CRC survivors.
Settings and methods - Phase 2 feasibility trial. Two hundred and twenty-four CRC survivors
within 12 months of completion of cancer treatment and without evidence of
persistent/recurrent disease will be recruited from four public hospitals in Hong Kong after
informed consent. Subjects will be randomized in a 2x2 factorial design for the two targeted
behaviours prescribed over 12 months. Primary outcome measure is whether the target levels
of PA and dietary intake could be met at the end of intervention. Secondary outcome measures
include: (1) magnitude of changes in PA level and dietary intakes; (2) rates and
determinants of compliance; (3) facilitators and barriers to behavioural change; (4)
measurement of theoretical constructs underlying PA and dietary interventions; (5) possible
health benefits and side effects (PA-associated injury and nutritional deficiency) arising
from the interventions. Outcome will be assessed at baseline, 6 months into intervention and
then at 0, 6 and 12 months post-intervention.
Impact - If proven feasible, our intervention programme would pave way for a large
randomized controlled trial testing the effect of PA and diet on the treatment outcome of
CRC.
| Status | Recruiting |
| Enrollment | 224 |
| Est. completion date | June 2017 |
| Est. primary completion date | December 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Histologically proven colorectal adenocarcinoma; 2. Within one year of completion of main cancer treatment Exclusion Criteria: 1. Persistent/recurrent disease upon recruitment; 2. Current cancer treatment; 3. Hereditary CRC syndromes; 4. Known contraindication to PA; 5. Illiteracy; 6. Weekly red/processed meat < 5 servings and daily refined grains < 2 servings 7. Weekly MPA > 300 minutes |
Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| China | Pamela Youde Nethersole Eastern Hospital | Hong Kong | |
| China | Princess Margaret Hospital | Hong Kong | |
| China | Queen Mary Hospital | Hong Kong | |
| China | Yan Chai Hospital | Hong Kong |
| Lead Sponsor | Collaborator |
|---|---|
| The University of Hong Kong | World Cancer Research Fund International |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Whether the PA and dietary intake targets are met at the end of intervention; | Whether the PA and dietary intake targets are met at the end of intervention; i.e. PA group: achieve PA targets or not Dietary group: achieve dietary target or not PA + dietary group: achieve both PA and dietary targets or not Control group: achieve PA or dietary target or not |
at the end of 12 months of intervention | No |
| Secondary | Magnitude of change in PA level using objective accelerometry | 6, 12, 18 and 24 months after start of intervention (i.e. interim, 0, 6 and 12 months post-intervention) | No | |
| Secondary | Magnitude of change in each component of dietary target using validated food frequency questionnaire (FFQ); | 6, 12, 18 and 24 months after start of intervention (i.e. interim, 0, 6 and 12 months post-intervention) | No | |
| Secondary | Rate and determinants of compliance with intervention; | Rates of compliance - measured by rate of completion of assignment; determinants of compliance measured by a questionnaire | at the end of 12 months of intervention | No |
| Secondary | Facilitators and barriers to intervention | Measured by (a) qualitatively during the last group meeting and (b) quantitatively by questionnaire | at the end of intervention | No |
| Secondary | Measurement of theoretical constructs underlying PA and dietary interventions | Using questionnaire specifically desinged to measure these theoretical constructs | 6, 12, 18 and 24 months after start of intervention (i.e. interim, 0, 6 and 12 months post-intervention) | No |
| Secondary | Other possible health benefits arising from the intervention | including Changes in body composition via body mass index (BMI) Changes in body fat and/or visceral fat via waist-hip ratio (WHR) and bioelectrical impedance analysis Physical fitness in the form of submaximal oxygen uptake as predicted by 6-minute ergometry Quality-of-life/mood via validated tools (SF12, FACT, HADS and PSS); |
at 12 and 24 months after start of intervention (i.e. at 0 and 12 months post-intervention) | No |
| Secondary | Possible side effects arising from the intervention | including PA-associated injury Dietary deficiency - (i) anaemia (haemoglobin level); (ii) energy and protein deficiency |
at 6, 12, 18 and 24 months after start of intervention (i.e. interim, 0, 6 and 12 months post-intervention) | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |